|
May 15
|
Karolinska Development’s Annual General Meeting 2025
|
|
May 13
|
Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US
|
|
May 7
|
Karolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025
|
|
May 5
|
Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation
|
|
Feb 14
|
Year-end Report - January-December 2024
|
|
Dec 9
|
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia
|
|
May 16
|
Karolinska Development’s Annual General Meeting 2024
|
|
Jan 9
|
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product
|
|
Dec 6
|
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates
|
|
Dec 4
|
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
|
|
Nov 28
|
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
|
|
Nov 17
|
Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone
|
|
Nov 17
|
Interim Report - January-September 2023
|